Transactions
2
Insider / DEXCOM INC
Sylvain Jereme M
EVP, Chief Financal Officer at DEXCOM INC
- Company
- DEXCOM INC
- Ticker
- DXCM
- First filing on record
- August 25, 2026
- Latest trade on record
- September 10, 2026
- SEC filings
- EDGAR ↗
Sylvain Jereme M, EVP, Chief Financal Officer at DEXCOM INC, has disclosed 2 transactions in DXCM since August 25, 2026: 0 purchases (0 open-market buys) and 2 sales, worth about $437K at the reported prices. The latest was filed September 14, 2026, 4 days after the trade.
Open-market buys
0
Sales
2
Avg. disclosure lag
3.5d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)
In the last 12 months Sylvain Jereme M made no purchases and 2 sales worth $437K. Dot size is the dollar amount.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
Sylvain Jereme M has traded 1 stock on record; the largest by dollars is DXCM.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
0 of 2 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| F | Shares withheld for tax | 1 | 1,451 | $134K |
| S | Open-market sale | 1 | 3,638 | $303K |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 2 | 0 | 2 · $437K |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| DXCM | Sell S | September 10, 2026 | September 14, 2026 | 4d | 3,638 | $83 | $303K | 10b5-1 plan | Form 4 ↗ | |
| DXCM | Sell F | August 22, 2026 | August 25, 2026 | 3d | 1,451 | $92 | $134K | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| September 14, 2026 | Form 4 | 0001093557-26-000173 | 1 | published | EDGAR ↗ |
| August 25, 2026 | Form 4 | 0001093557-26-000158 | 1 | published | EDGAR ↗ |
Other insiders at DEXCOM INC
- Brown Michael Jon EVP Chief Legal Compliance Off 3 rows
- Stern Sadie EVP Chief People & Culture Off 3 rows
- AUGUSTINOS NICHOLAS Director 2 rows
- Boehnlein Glenn S Director 2 rows
- Leach Jacob Steven President, CEO, and Director 1 row
Everyone on file, with contracts and lobbying under the company's name: DEXCOM INC.
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Rule 10b5-1 trading plans The plan must be set up when the insider has no important non-public information.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 2 | 2 | August 25, 2026 | September 14, 2026 | Form 4 list on EDGAR |
Site built October 27, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.